Diagnostic HER2DX-guided Treatment for Patients wIth Early-stage HER2-positive Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The primary goal of the DEFINITIVE trial is to demonstrate the effectiveness of the HER2DX diagnostic assay in enhancing the management of patients with early-stage HER2- positive breast cancer. Patients randomized to arm A will receive adjuvant treatment by physician´s choice, blinded to the diagnostic HER2DX test results. Patients randomized to Arm B will receive personalized treatment according to HER2DX results.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma co najmniej 18 lat i wyraził zgodę na udział.
- •Ogólny stan zdrowia pacjenta pozwala na leczenie.
- •Rak piersi jest potwierdzony badaniem tkanki, nie jest zaawansowany (nie ma przerzutów w inne miejsca ciała).
- •Wyniki badań wskazują na obecność receptora HER2 (HER2-dodatni rak).
- •Guzy w piersiach mogą być pojedyncze lub mnogie (w tym w różnych częściach piersi), pod warunkiem, że będą przebadane i okażą się HER2-dodatnie.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- February 20, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (29)
MUG-Univ.-Klinik für Frauenheilkunde und Geburtshilfe, Klinische Abteilung für Gynäkologie
Graz, Austria
Lkh Hochsteiermark-Leoben
Leoben, Austria
Ordensklinikum Linz, Barmherzige Schwestern, Bhs
Linz, Austria
Uniklinikum Salzburg
Salzburg, Austria
Universitätsklinikum St.Pölten
Sankt Pölten, Austria
Hanusch Krankenhaus
Vienna, Austria
Klinik Hietzing, Gynäkologische Abteilung - Karl Landsteiner Institut für gyn. Onkologie
Vienna, Austria
Medizinische Universität Wien, Allg. Gynäkologie und Gyn. Onkologie
Vienna, Austria
Klinikum Wels-Grieskirchner
Wels, Austria
Sainte-Catherine - Institut du Cancer Avignon-Provence
Avignon, France
Polyclinique Bordeaux Nord
Bordeaux, France
Centre León Bérard
Léon, France
Institut Paoli Calmettes
Marseille, France
Institut de Cancérologie de Lorraine
Nancy, France
Gustave Roussy
Paris, France
Oncopole Claudius Regaud, IUCT-Oncopole
Toulouse, France
Sheba Medical Center
Ramat Gan, Israel
Istituto Europeo di Oncologia
Milan, Italy
Institute Oncology Veneto
Padova, Italy
Instituto Catalán de Oncología (ICO) - Hospitalet
L'Hospitalet de Llobregat, Spain
Hospital Universitario Clínico San Cecilio
Granada, Spain
Hospital Clínico Universitario de Santiago
Santiago de Compostela, Spain
Complejo Asistencial Universitario de León
León, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Hospital Clínico Universitario Virgen de Arrixaca
Murcia, Spain
Hospital Universitario Sant Joan de Reus
Reus, Spain
Hospital Universitario de Basurto
Bilbao, Spain
Instituto Catalán de Oncología (ICO) - Badalona
Badalona, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Trial contact
Tomás Pascual, MD
Olga Martínez, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.